MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: Association between SNP309 GG genotype and tumor Breslow thickness

Journal of Human Genetics

Volumn 55, Issue 8, 2010, Pages 518-524

  Capasso, Mario ^a   Ayala, Fabrizio ^b   Avvisati, Rosa Anna ^a   Russo, Roberta ^a   Gambale, Antonella ^a   Mozzillo, Nicola ^b   Ascierto, Paolo Antonio ^b   Iolascon, Achille ^a,c  

^a CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Breslow thickness; cutaneous melanoma; MDM2; p53; SNP

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ADULT; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS MELANOMA; DISEASE COURSE; FEMALE; GENE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; ONSET AGE; P53 ARG72PRO GENE; POLYMERASE CHAIN REACTION; POPULATION GENETICS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SEQUENCE ANALYSIS; SEX RATIO; SINGLE NUCLEOTIDE POLYMORPHISM; SNP309 GENE; TUMOR VOLUME;

ADULT; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; MALE; MELANOMA; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77957576133     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1038/jhg.2010.62     Document Type: Article

References (33)

1. Momand, J., Zambetti, G. P., Olson, D. C., George, D. & Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237-1245 (1992).
2. Michael, D. & Oren, M. The p53-Mdm2 module and the ubiquitin system. Semin. Cancer Biol. 13, 49-58 (2003).
3. Zhang, Z. & Zhang, R. p53-independent activities of MDM2 and their relevance to cancer therapy. Curr. Cancer Drug Targets 5, 9-20 (2005).
4. Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C. et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119, 591-602 (2004).
5. Harris, S. L., Gil, G., Robins, H., Hu, W., Hirshfield, K., Bond, E. et al. Detection of functional single-nucleotide polymorphisms that affect apoptosis. Proc. Natl Acad. Sci. USA 102, 16297-16302 (2005).
6. Millikan, R. C., Heard, K., Winkel, S., Hill, E. J., Heard, K., Massa, B. et al. No association between the MDM2-309 T/G promoter polymorphism and breast cancer in African-Americans or Whites. Cancer Epidemiol. Biomarkers Prev. 15, 175-177 (2006).
7. Park, S. H., Choi, J. E., Kim, E. J., Jang, J. S., Han, H. S., Lee, W. K. et al. MDM2 309T>G polymorphism and risk of lung cancer in a Korean population. Lung Cancer 54, 19-24 (2006).
8. Toyama, T., Zhang, Z., Nishio, M., Hamaguchi, M., Kondo, N., Iwase, H. et al. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res. 9, R34 (2007).
9. Wilkening, S., Bermejo, J. L. & Hemminki, K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis 28, 2262-2267 (2007).
10. Firoz, E. F., Warycha, M., Zakrzewski, J., ollens, D., Wang, G., Shapiro, R. et al. Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma. Clin. Cancer Res. 15, 2573-2580 (2009).
11. Nan, H., Qureshi, A. A., Hunter, D. J. & Han, J. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer. Cancer Causes Control 20, 171-179 (2009).
12. Hong, Y., Miao, X., Zhang, X., Ding, F., Luo, A., Guo, Y. et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res. 65, 9582-9587 (2005).
13. Zhang, X., Miao, X., Guo, Y., Tan, W., Zhou, Y., Sun, T. et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum. Mutat. 27, 110-117 (2006).
14. Hirata, H., Hinoda, Y., Kikuno, N., Kawamoto, K., Suehiro, Y., Tanaka, Y. et al. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin. Cancer Res. 13, 4123-4129 (2007).
15. Talseth, B. A., Meldrum, C., Suchy, J., Kurzawski, G., Lubinski, J. & Scott, R. J. MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients. Int. J. Cancer 120, 563-565 (2007).
16. Schmidt, M. K., Reincke, S., Broeks, A., Braaf, L. M., Hogervorst, F. B., Tollenaar, R. A. et al. Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res. 67, 9584-9590 (2007).
17. Stefanaki, I., Stratigos, A. J., Dimisianos, G., Nikolaou, V., Papadopoulos, O., Polydorou, D. et al. p53 codon 72 Pro homozygosity increases the risk of cutaneous melanoma in individuals with dark skin complexion and among noncarriers of melanocortin 1 receptor red hair variants. Br. J. Dermatol. 156, 357-362 (2007).
18. Li, C., Chen, K., Liu, Z., Wang, L. E., Gershenwald, J. E., Lee, J. E. et al. Polymorphisms of TP53 Arg72Pro, but not p73 G4C147gt;A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma. J. Invest. Dermatol. 128, 1585-1588 (2008).
19. Gwosdz, C., Scheckenbach, K., Lieven, O., Reifenberger, J., Knopf, A., Bier, H. et al. Comprehensive analysis of the p53 status in mucosal and cutaneous melanomas. Int. J. Cancer 118, 577-582 (2006).
20. Shen, H., Liu, Z., Strom, S. S., Spitz, M. R., Lee, J. E., Gershenwald, J. E. et al. p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. J. Invest. Dermatol. 121, 1510-1514 (2003).
21. Chung, E. S., Sabel, M. S. & Sondak, V. K. Current state of treatment for primary cutaneous melanoma. Clin. Exp. Med. 4, 65-77 (2004).
22. Balato, N., Gaudiello, F., Balato, A. & Monfrecola, G. Sun habits in the children of Southern Italy. J. Am. Acad. Dermatol. 57, 883-887 (2007).
23. Carli, P., Naldi, L., Lovati, S. & La Vecchia, C. The density of melanocytic nevi correlates with constitutional variables and history of sunburns: a prevalence study among Italian schoolchildren. Int. J. Cancer 101, 375-379 (2002).
24. Paulin, F. E., O'Neill, M., McGregor, G., Cassidy, A., Ashfield, A., Ali, C. W. et al. MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism. BMC Cancer 8, 281 (2008).
25. Breslow, A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann. Surg. 172, 902-908 (1970).
26. Capasso, M., Ayala, F., Russo, R., Avvisati, R. A., Asci, R., Iolascon, A. A predicted functional single-nucleotide polymorphism of bone morphogenetic protein-4 gene affects mRNA expression and shows a significant association with cutaneous melanoma in Southern Italian population. J. Cancer Res. Clin. Oncol. 135, 1799-1807 (2009).
27. Mocellin, S., Verdi, D. & Nitti, D. DNA repair gene polymorphisms and risk of cutaneous melanoma: a systematic review and meta-analysis. Carcinogenesis 30, 1735-1743 (2009).
28. Bond, G. L., Hirshfield, K. M., Kirchhoff, T., Alexe, G., Bond, E. E., Robins, H. et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormonedependent manner. Cancer Res. 66, 5104-5110 (2006).
29. Bond, G. L., Menin, C., Bertorelle, R., Alhopuro, P., Aaltonen, L. A. & Levine, A. J. MDM2 SNP309 accelerates colorectal tumour formation in women. J. Med. Genet. 43, 950-952 (2006).
30. Balch, C. M., Soong, S. J., Gershenwald, J. E., Thompson, J. F., Reintgen, D. S., Cascinelli, N. et al. Prognostic factors analysis of 17, 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 19, 3622-3634 (2001).
31. Fortes, C., Mastroeni, S., Sera, F., Concolino, F., Abeni, D., Melchi, F. et al. Survival and prognostic variables of cutaneous melanoma observed between 1995 and 2000 at Istituto Dermopatico Dell'Immacolata (IDI-IRCCS), Rome, Italy. Eur. J. Cancer Prev. 15, 171-177 (2006).
32. Gryshchenko, I., Hofbauer, S., Stoecher, M., Daniel, P. T., Steurer, M., Gaiger, A. et al. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J. Clin. Oncol. 26, 2252-2257 (2008).
33. Box, N. F. & Terzian, T. The role of p53 in pigmentation, tanning and melanoma. Pigment Cell Melanoma Res. 21, 525-533 (2008).